ValuEngine upgraded shares of Retrophin (NASDAQ:RTRX) from a sell rating to a hold rating in a report published on Wednesday, March 7th.
Several other equities research analysts also recently weighed in on the stock. BidaskClub raised shares of Retrophin from a hold rating to a buy rating in a research note on Saturday, March 3rd. Zacks Investment Research downgraded shares of Retrophin from a hold rating to a sell rating in a research note on Thursday, January 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The company has a consensus rating of Hold and a consensus target price of $44.00.
Retrophin (RTRX) traded up $0.04 during trading on Wednesday, reaching $25.35. 75,820 shares of the company were exchanged, compared to its average volume of 342,373. Retrophin has a 52 week low of $15.55 and a 52 week high of $26.44. The company has a current ratio of 3.80, a quick ratio of 3.74 and a debt-to-equity ratio of 0.15.
Institutional investors and hedge funds have recently made changes to their positions in the company. Trexquant Investment LP purchased a new stake in shares of Retrophin in the third quarter valued at $203,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Retrophin in the third quarter worth about $212,000. Campbell & CO Investment Adviser LLC bought a new position in shares of Retrophin in the third quarter worth about $249,000. Teacher Retirement System of Texas bought a new position in shares of Retrophin in the fourth quarter worth about $256,000. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Retrophin in the third quarter worth about $349,000.
TRADEMARK VIOLATION NOTICE: This news story was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.thelincolnianonline.com/2018/03/15/retrophin-rtrx-upgraded-by-valuengine-to-hold.html.
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.